Diazepam, marketed under the brand name Valium, is a benzodiazepine medication with a broad range of clinical applications. It is primarily prescribed for the management of anxiety disorders, acute alcohol withdrawal, skeletal muscle spasms, and as an adjunct therapy for certain seizure disorders. Approved by the FDA in 1963, diazepam works by enhancing the effects of GABA, a neurotransmitter that calms abnormal overactivity in the brain.

The drug is available in multiple formulations, including oral tablets, oral solutions, rectal gels, injectable solutions, and more recently, a nasal spray for emergency seizure control. While effective, diazepam carries significant risks. It is classified as a Schedule IV controlled substance due to its high potential for abuse, misuse, and addiction. Physical dependence can develop even with therapeutic use, and abrupt discontinuation can precipitate life-threatening withdrawal symptoms, including seizures.

Common side effects include drowsiness, fatigue, muscle weakness, and ataxia. Dangerous interactions occur with opioids, alcohol, and other CNS depressants, which can cause profound sedation, respiratory depression, coma, and death. Paradoxical reactions such as agitation, irritability, and hallucinations may occur, particularly in children and the elderly. Diazepam is contraindicated in patients with myasthenia gravis, severe respiratory insufficiency, severe hepatic insufficiency, and sleep apnea syndrome.

For more detailed pharmacological information, resources like the NCBI Bookshelf (https://www.ncbi.nlm.nih.gov/books/) and DailyMed (https://dailymed.nlm.nih.gov/) provide comprehensive clinical data. The FDA (https://www.fda.gov/) offers official prescribing information and safety communications. Patients should always consult their healthcare provider before starting or stopping this medication.

procedural sedation

diazepam